The FDA has approved once-monthly dosing of Elrexfio (elranatamab-bcmm) for certain patients with relapsed or refractory multiple myeloma.

This analysis indicates that proposed Medicaid reforms would have far-reaching consequences beyond federal budget savings, including negative health outcomes, economic losses, and health care system ...

The US Food and Drug Administration (FDA) has granted priority review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle invasive bladder ...

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

Chemotherapy can increase mutation burden and change the cell population structure of normal blood, which contributes to long-term adverse effects such as second malignancies and infertility, ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Thousands of workers at federal health agencies lost their jobs this week after a US Supreme Court ruling cleared the way for the Trump administration to move forward with major staffing cuts.

Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers,” researchers wrote.

Biomarker testing rates before first-line treatment increased over time, and rates of biomarker testing increased between first-line and second-line treatment.

The NIH is planning to limit how much publishers can charge NIH-supported scientists to make their research findings publicly available.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.